Boehringer Ingelheim

Disparities in clinical trials must become a thing of the past. Inclusion of race, sex, age, genetics, demographics and geographies in clinical trial designs allows us to achieve relevant healthcare solutions that meet the needs of diverse patient populations. Read more here: https://lnkd.in/erYSU5db #ClinicalTrials #Diversity

#NEWS: Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics, is moving to the next phase in clinical development. Based on the positive data from our first clinical studies and the switch to an improved antibody we aim to provide innovative immuno-oncology treatments to the benefit of more people. Learn more: https://bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment

“Vision is more than just a function, it’s the sense that people most value, it connects individuals to their way of life.” Read more from our Director of Cardio-Metabolic Diseases Research/Retinal Health, Remko Bakker, as he reflects on our research and development program in #RetinalHealth 👉 https://lnkd.in/eb5YN9Pj

It's essential to raise awareness of the impact that diseases like generalized pustular psoriasis (#GPP) have on people's lives. By collaborating with patient organizations like IFPA, we aim to support their efforts to empower people living with GPP.

#HCP: Tango is a dance in which 2 people communicate through their movements. In the same way, it also takes 2 tests to get the full picture about #ChronicKidneyDisease (CKD). Follow clinical guidelines from diabetes and kidney organizations and issue 2 tests – an eGFR (blood) and UACR (urine) test. Learn more here: https://lnkd.in/eHhyKVMc

Together with the Advisory Board on Cat Diseases (ABCD) we proudly recognize Dr. Katharina Zwicklbauer (Ludwig-Maximilians-Universität München) with the 2024 Young Scientist Award.   Katharina's research on feline infectious peritonitis (FIP), a fatal disease caused by a feline coronavirus, that mostly affects young cats, made important contributions to the field of feline medicine. Just three years ago, there were no treatment options available. Now, there is a whole new product class that we still need to fully explore. In her controlled study, Katharina evaluated different oral formulations of these new antivirals and showed promising results on the clinical evolution and virological parameters. #LifeForward

#NEWS: We're launching the Phase 1 study of BI 3034701, a potential first-in-class, triple agonist obesity treatment developed in our partnership with Gubra. Discover how we are advancing our comprehensive strategy at https://bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation

Imagine you're a veterinarian. You’re an expert in your field. Still, some treatments are complicated - like stabilizing a diabetic cat on insulin. Will the cat be patient enough for the necessary glucose curves? Will pet owners be able to handle giving injections twice a day? And then, a new treatment comes around, making it suddenly more convenient to manage the disease. How would you feel? Innovations can make all the difference. That's why we were excited to have Dr. Samantha Taylor FRCVS at the ISFM 2024 Feline Congress. As the Feline Specialist Advisor for ISFM, she was discussing a new treatment that makes life easier for cats and their owners. Diabetes is one of the most common endocrine diseases in cats. That's why peer-to-peer discussions about latest treatment innovations are so important. #LifeForward

As #pridemonth comes to an end, it's important to remember that #diversity remains a significant topic in many areas, including #clinicaltrials, where too many people are invisible. We need to ensure everyone is represented and has the same opportunity to benefit from medical progress. Read more about diversity in clinical trials here: https://lnkd.in/erYSU5db

As an ally of the LGBTQIA community, our colleague Jasmin sees respect in private as well as in working life as a core value. Listen to the story of her friend, who is transgender, and the difference respect makes in his job. 👆 #PrideMonth